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The protdem of post4hrombo~yttc re&usion can be sp. 
pmached ia severat ways. 1) Better tbmmtmtytic qents with 
Jonaer duratton of eUects and more powerful umpcrtk~ 
One of the most exciting and challenging fields in cardiology 
over the last few years has been the development of short- 
term interventions aimed at achieving myocardial reperfu- 
sion in patients with acute infarction. Reperfusion can be 
accomplished pharmacologically with the use of thrombolyt- 
ic drugs, and mechanically with balloon angioplasty or 
coronary artery bypass surgery. Thrombolytic therapy has 
clear advantages over the other two forms of therapy in that 
it can be administered promptly after the presentation of the 
patient with acute myocardial infarction, given intr-ve- 
nously and instituted in community hospitals without the 
need for immediate cardiac catheterization. 
One of the problems associated with hrombolysis has 
been the development of acute coronary reocclusion, which 
is associated with further myocardial ischemia, exrension of 
infarction and an increased mortality. Over the 1~: 2 years, 
we have learned agreat deal about the causes ot :eocclusion, 
and intensive research is now being focused on the d!evelop 
ment of thrombolytic drugs with associated anticoagulant 
properties and on more powerful antithrombotic agl:nts. We 
will analyze I) the processes of platelet activation and 
thrombus formation during acute myocardial infarction, 2) 
the pathophysiologic events that follow thrombolysis and 
predispose to coronary reocclusion, and 3) future antithrom- 
botic approaches in the prevention of reocclusion. 
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tnfarction treated with thrombotytk agmts. 3) Pepttde in- 
bthttors of tbrom~ and monoctonat antibodte3 agatnst 
ptatekt gtyceprotetn receptors and adbestve - 
arc potenttatty et%ettve tnhtbttors of platetet aggregatton and 
tbmmhos fomratton during or after tbmmbotytie therapy. 
(J Am Coil Caniio11988:12:78A44A) 
Platelet Activation and Thrombus Formation 
During Acute Myocardial Infarction 
Recent clinical, pathologic and experimental observa- 
tions have improved our understanding of the pathogenesis 
of acute coronary syndromes. Postmortem studies (1,2) have 
demonstrated the presence of atherosclerotic plaque rupture 
or fissuring with secondary thrombus formation in the ma- 
jority of fatal cases of unstable angina, myocardial infarction 
and ischemic sudden death. 
Consquencos of plaque rupture. After deep vessel wall 
injury, such as occurs during plaque rupture, fibrillar colla- 
gen (particularly type 1) is exposed to the circulation. Ex- 
posed collagen is a strong stimulus for platelet aggregation 
and thrombus formation. Experimentally, when type I col- 
lagen is exposed to flowing blood in the perfusion chamber 
designed in our laboratory by Badimon et al. (3), marked 
platelet deposition occurs. In addition, platelet deposition 
increases when blood flow is exposed to higher shear rates, 
similar to those found in coronary stenoses. The platelet 
thrombus eventually occludes the vessel lumen and is not 
removed by high blood flow (Fig. 1). This experiment mimics 
the hemorrheologic conditions that occur during plaque 
rupture, where exposed collagen and high shear rates pro- 
mote platelet activation and the rapid growth of pla?elet 
thrombi. The deceleration of blood flow that occurs in the 
poststenotic area produces Row separation and recirculation 
zones that promote the deposition of fibrin. This leads to the 
formation of a fixed platelet thrombus in the area of luminal 
stenosis and a large meshwork of fibrin and trapped red 
blood cells in the poststenotic area (4). These findings are 
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Figure 1. Platelet deposition on type I collagen (which resembles 
collagen exposed during deep vessel injury) versus exposure time at 
different shear rates (in seconds-!) solid c~les 2 3,380; opco 
circles = 1,690; triangles = 212. Note tbdt platelet deposition 
increases progressively with time ani 1b;rc IS no loss of platelets 
even at high shear rates, which suggcs~ that the thrombus is fixed. 
(Reprinted with permission from Badlmoo et al. [31 and the Amer- 
ican Hear! Association, Inc.) 
clinically relevant in the context of the pathogenesis of Q 
wave myocardial infarction. In these patients, plaque rup- 
ture leads to the exposure of vessel wall collagen and 10 an 
increase in shear rate, both of which favor the formation of 
a fixed and occlusive thrombus (5). 
Processes by whib platefets and clotting Factors are acti- 
Wed. After plaque injury, exposed collagen, in addition to 
other mediators, induces platelet aggregation. Most platelet 
agomy, \cem lo act through the hydrolysis of platelet 
membrane phosphatidylinositol by phospholipase C. which 
results in the mobilization of calcium from the platelet dense 
tubular system. Calcium, in turn, is an important mediator of 
platelet activation, which can occur by means of three 
metabolic pathways: thrombinkollagen-dependent, adeno- 
sine diphosphale (ADPI-dependent and arachidonate-depen- 
dent (6)  (Fig. 2). 
lo the first pathway. exposed collagen from the vessel 
wall and thrombin generated by the activation of the coagu- 
Son ~esz& are powerful and independent platelet activa- 
tors, perhaps through the release of a “platelet-activating 
factor.” The second pathway is mediated by ADP, whicb 
may be released from hemolyzed red cells in the area of 
vessel injury. This agonist s;mulates the discharge of cal- 
cium from the platelet dense tubular system and promotes 
the contraction of the platelet, with the subsequent release of 
its granule contents. Released ADP and serotonin stimulate 
adjacent platelets, further enhancing the process of platelet 
activation. Finally, the third pathway is mediated by arachi- 
donate, which is released from the platelet membrane by the 
stimulatory activity of collagen, thrombin, ADP and seroto- 
nin. Arachido,late is converted lo thrombnxane A2 by the 
sequential action of cyclooxygenase and thromboxane syn- 
thetase. Thromboxane A2 noIOt only promotes further platelet 
aggregation, but also is a potent vasoconstrictor. 
Any or  all of these three pathways induce the contraction 
of tk plate!et, with the subsequent exposure of platelet 
zccptors. namely, the glycoprotein Ilb-Illa (7). Adhesive 
macromolecules inc!uding fibrinogen, von W#ebrand factor, 
Achvotion 0; membrone receptors 
(odhesnm and oggrrgotmn) 
Fire 2. Mechanisms of platelet acli- 
vation. Most plarelet agonists slimulate 
Ihe mobilizaGon of calcium from the 
dense tubular system. Calcium is an 
important mediator of platelet aaiva- 
tion, which oeeurs by means of three 
metaholie pathways dependent on 
1 
lhrombin-collagen, adenosine diphos- 
J 
phate (ADP) and arachidonate. Cyclic 
adenosine monophosphate (AMP) in- 
hibits calcium mobilization. Throm- 
hoxane A, (TxAJ and prostacyc!in 
(PGI,) nave opposite Sects on adeayl 
cyclase and the level of CAMP. Note 
that thrombin and collagen can indc- 
pendently activate platelets probably 
by means of a platelet activating factor 
(see text). ATP = adenosinc Iriphos- 
phate. 
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Intrinsic Extrinsic 
and possibly fibronectin bind to glycoprotein Ilb-llla and 
form bridges between neighboring platelets (6,7), thereby 
ulaying an essential role in the process of platelet aggrega- 
iion (Fig. 3). 
Activation of clotting mechanism. During plaque rupture, 
in addition to platelet deposition in the injured area, the 
clotting mechanism is activated by the exposure of the 
deendothelialized vascular surface (intrinsic pathway) and the 
release of tissue factor (extrinsic pathway) (Fig. 3). The 
activation of the coagulation cascade leads to the generation 
of thrombin which, as mentioned before, is a powerful platelet 
activator that also catalyzes the formation and polymerization 
of fibrin. Fibrin is essential in the stabilization of the platelet 
thrombus and allows it to resist removal by high intravascular 
pressure and shear rate. These basic concepts have clinical 
relevance in the context of myocardial infarction, where 
plaque rupture exposes collagen, which activates platelets 
and the coagulation system and results in the formation of a 
tixed and occlusive platelet/fibrin thrombus. 
Coronary kocrlusion After Thrombolysis 
The goal of thrombolytic therapy is to restore myocardial 
perfusion through a previously occluded vessel in the short- 
est possible time to prevent or limit myocardial necrosis. 
The ideal thrombolytic agent would produce the highest rate 
of reperfusion and the lowest incidence of complications, 
namely, bleeding and rethrombosis (8). We will anaiyze the 
pathogenetic mechanisms underlying rethrombosis after 
thrombolysis. 
The incidence of rethrombosis after successful coronary 
thrombolyk is approximately 5 to 20% (9). To date, two 
Figarc 3. L&t, Scheme of the binding of adhesive macromolecules 
to platelet membrane glycoproteins. Fibrinogen binds to the glyco- 
protein Ilb-Illa-Ca” complex (gamma chain) constituting the essen- 
tial reaction in platelet aggregation. Von Willebrand factor (VWFI 
can either bind to glycoprotcin lb or IlbIIIa-Ca+t compkx (alpha 
chain) ie association with fibronectin, thus contributing to both 
platelet adhesion and agpregation. Collagen may bind to glycoprw 
tein la and possibly oarlicipate in the process of adhesion. lttgkt, 
Scheme of ihe biochemicai activation of the coagulation system. 
F = factor. (Modified from Davis JA, McNichol G. Haemostasis and 
thrombosis. In: Weatherall DJ, Ledingham JEE, Warett DA, eds. 
Oxford Textbook of Medicine. Oxford, New York. Oxford Press, 
1983:19.) 
main contributing factors for the development of re:hrom- 
bosis have been identified: I) altered hemorrheologic condi- 
tions associated with the persister! !uminal stenosis caused 
by the residual thrombus (lo), and 2) persistence; of a strong 
thrombogenic stimulus caused by the residual thrombus 
itself. 
ResMual tumid stenosis. To investigate the altered he- 
morrheology seen in cases of significant coronary stenosis, 
we used the perfusion chamber mentioned previously (3), in 
which we exposed arterial blood from a pig’s carotid artery 
to di!?erent substrates and at different degrees of wall shear 
rate and iuminal stenosis. Using stripped tunica media as the 
exposure substrate and allowing the arterial blood to circu- 
late through conduits with diierent degrees of luminal ste- 
nosis, we were able to demonstrate a marked increment in 
platelet deposition when higher degrees of stenosis were 
used (Fig. 4) &II). The reason for this phenomcaon is that, 
in a system with a mild obstruction to flow, the shear rate, 
which is the difference in fluid velocity (or gradient) between 
Figare 4. Using the perfusion chamber, blood from the carotid 
artery of pigs was exposed lo injured arterial tissue at various 
degrees of eccentric stenosis. Tbe Dercent of olatelers dewsikd 
(P6) at the peak area of stenosis (Sj was compared with tie total 
platelets deposited in the exposed tissue. Note the significant 
increase in deposited platelets at higher degrees of luminal stenosis. 
(Reproduced with permissbn from Fuster et ai. [5] and the Ameri- 
can Heart Association. Inc.) 
the center and the periphery of the circulating mass, is low. 
However, with higher degrees cf stenosis, th.: shear rate is 
markedly increased. This facilitates the interaction of olate- 
lets andihe vessel wall and promotes platelet deposit& on 
deposition in the affected area. which suggests that the 
the exposed surface (12). Inadditiortit appe&that under 
thiombus that remains after spontaneous l&is or platelet 
disaggregation is markedly thrombogenic and stimulates the 
high shear rate conditions, red blood cells contribute to the massive deposition of platelets on its surface (5). With con- 
delivery of platelets to the injured area by forcing them 10 tinued perfusion, a recurrent cycle of platelet disaggregation 
travel in the periphery of the circulating mass (12). 
The pro&o& importance of residual stenosis ajler 
followed by massive platelet deposition was observed. This 
finding is supported by clinical s!udies (I?,!!?) that have 
thrombolysis has been clearly demonstrated by a number of shown an im-rcased risk of rethrombosis when a residual 
clinical studies (13-17). A residual stenosis >75% luminal thrombus is seen angiographically tier thrombolysis as com- 
diameter (13) or a cross-sectional area <0.4 mm* (14) was oared v,lth casea without evidence of a residual thrombus. 
associated with an increased risk of early rethrombosis. 
(1s) showed-that a residual 
Thrre have been recent provocative experimental and 
Furthermore, Badger at al. clinics/ studies (20-24) that have suggested an increase in 
luminal diameter CO.6 mm or a Thrombolvsis in Mvocardial 
Infarction (TIMI) perfusion grade 1 or 2 ipartial perfusion) 
platelet activation and thrombin activity after the adminis- 
iration of streptokinase or  recombinant tissue plasminogen 
(18) wds associated with higher an&graphic reocclusion at 5 _ _ _ 
weeks and a higher 1 ye& mortality rate. These clinical 
activator (r&PA). Fitzgerald et al. (20) observed a marked 
elevation in plasma and urinary metabolites of thromboxane 
observations are supported by data from our laboratory A, after the administration of strentokinase in natients with 
(3,111, which show that higher degrees of luminal stenosis acite mvocardial infarction. This effect was-not seen in 
and hitther shear rates are both associated with increased patients pretreated with aspirin. In ano!her study, Eisenberg 
et al. (21) showed an increase in librinopeptide A (which is 
released bv the action of thrombin on Cbrinoaen) immedi- 
ately after- thrombolytic therapy with strept&nase in pa- 
soy, we have found that the presence of a residual thrombus, 
which is common after thro;nbolysis (IO), is one of the most 
tients with acute myocardial- &rction. -Although these 
elegant studies suggest a direct stimulatory effect of strepto- 
powerful thrombogenic surfaces ever encountered in the kinase on olatekt and thrombin activity. their conclusions 
laboratorv. In the ex vivo model using the De&ion cham- 
ber, we measured the degree of dep&tion of indium-I I I- 
must be i;terpreted with caution. We believe that these 
prothrombotic- events seen after thrombolysis may ret&t 
labeled platelets on stripped tunica media exposed to dii- the wwerful thrombogenic effects exerted by the residual 
ferent degrees of stenosis (Fig. 5) (11). When the stenosis 
was severe (80% of luminal &meter), platelet deposition 
throibus on both p&lets (11) and thrombin activity (25) 
and by the altered hemorrheologk conditions, as described 
increased with time as a result of the increased shear rate. earlier. The clinical imdications of the studies just men- 
After 30 mitt of perfusion, platelet deposition and associated tioned in terms of po&thrombolysis reperfusioi and re- _. - . . . . . . . . fibrin fOIImt lOII  abNpUy deCrCaSed, probat)ly beCaUSe O f  thrombosis remain to be defined. 
Figure 5. Using the same model as in Figure 4, a continuous 
scintigraphic image of the events that occurred during perfusion of 
an area with 80% stenosis. The corresponds 10 the peak 
area of stenosis and is exoresxd as iridium-I I I excess activilv with 
respect 10 blogd. Note tbbt at 30 min of pemsion there is an &up! 
decrease in indium counts followed bv a r&d increase. This 
suggests spontaneous thrombolysis or  ilatekt hisaggregation fol- 
lowed by massive platelet deposition in the atfected area (see text). 
(Reproduced with permission from Fuster et al. IS] and Ihe Ameri- 
can-Heart Associaiion, Inc.) 
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Antithrombotic Therapy After Thrombolysis 
After the preceding discussion on the potential faclors 
that lead to rethrombosis, an important querrkn remains. 
What is the best antithrombotic approach for preventing 
reocclusion? As we stated before, in spite of high rates of 
reperfusion achieved with different thrombolytic agents, the 
incidence rate of acute reocclusion is about 5 to 20%, and it 
occurs even in patients on full anticoagulant therapy (26). 
Active research is being done to develop a better antithrom- 
botic regimen that will be able to reduce the rate of re- 
thrombosis and its associated morbidity and mortality. New 
approaches in the prevention of reocclusion include I) 
improvement in thrombolytic agents, 2) use of currently 
available antithrombotic drugs, and 3) peptide inhibitors of 
thrombin and monoclonal antibodies directed against plate- 
let receptors and adhesive macromolecules. 
Improvement in thrombotytk agents. Currently available 
thrombolytic agents act directly or indirectly as activators of 
plasminogen (8). These agents are streptokinase, anisoylated 
plasminogen-streptokinase activator complex (APSAC), uro- 
kinase. r&PA and recombinant single chain urokinase plas- 
minogen activator (scu-PA). These compounds have different 
pharmacologic properties and hemaiologic effects. Although 
they are associated with a high (60 to 70%) rate of repelfusion 
if used early after myocardial infarction, the failure rate in 
terms of clot lysis is still between 20 and 40% (8). 
One approach for the prevention of reocclusion is the use 
of drugs that produce a long proreolytic state. An agent that 
offers certain advantages over the others is APSAC because it 
car be administered as an intravenous bolus, has a long 
half-life and is associated with a lower rate of rethrombosis 
(about lo%), perhaps owing to its long duration of action 
(9.27.28). Moreover, a recent large randomized double-blind 
placebo-controlled trial of APSAC in acute myocardial infarc- 
tion (29) showed a remarkable 47% reduction in the 30 day 
mortality rate, which was maintained in the 1 year follow-up 
study. Alternatively, a prolonged maintenance infusion of 
rt-PA (for an additional 4 to 6 h) has been used in an attempt 
to reduce the reocclusion rate, but the results are controver- 
sial and the number of patients studied is small (30.31). 
A second approach to preventing reocclusion is focused 
on the development of more effective thrombolytic agents 
that can achieve enhanced clot lysis and vessel patency. A 
method that is evolving is the use of synergistic combina- 
tions of thrombolytic agents with different mechanisms of 
fibrin specificity, such as r&PA and scu-PA (32). 
A third approach is rhe developmenr of long-acting lyric 
agents that also create an antithrombotic environment in the 
area of the residuai thrombus. In fact, streptokinase, which 
is not as fibrin-specific as &PA, causes fibrinogenolysis with 
the associated production of fibrinogen degradation prod- 
ucts. As a result of these effects, platelet aggregation is 
impaired (fibrinogen is necessary for normal platelet aggre- 
gation) and the degradation products have anticoagulant and 
polymerization-inhibiting activities (9). The benefits and 
risks of the use of long-acting lytic agents with strong 
antithrombotic properties need to be explored further. 
Currently avallabk rntlthrombotk agents. As mentioned 
earlier in this report, platelet activation in the area of clot 
lysis, which is secondary to altered hemodynamics and high 
shear rates and to the exposure of a residual thrombogenic 
surface, is an important contributor to thrombus formation 
and vessel occlusion (8). Therefore, platelet inhibitors may 
play a role in the prevention of reocclusion (9. Compelling 
data come from the recently completed Second International 
Study of Infarct Survival (ISIS-2) trial (33). In this study, 
more than 17,000 patients with suspected acute myocardial 
infarction were randomized to aspirin or intravenous strepto- 
kinase, the combination of both or placebo within 24 h of the 
onset of symptoms. This impressive study showed a reduc- 
tion in 5 week vascular mortality rate of 23% in the aspbin- 
treated group, 25% in the streptokinase-treated group and 
42% in patients treated with both agents. Aspirin probably 
acts by preventing rethrombosis after spontaneous or strep 
tokinase-induced vessel reperfusion. It is also of interest that 
streptokinase was effective even when given after 6 h and up 
to 24 h from the onset of symptoms, although its maximal 
effectiveness was obtained when given in the first 3 h after the 
onset nf infarction. Although the explanation for this finding is 
only speculative, the generalized tibrhtogenolytic and antr- 
thrombotic effects of streptokinase may eontribule to the 
maintenance of vessel patency and the prevention of reocclu- 
sion (34). In addition, the reduction in blood vir.ssity induced 
by streptokinase (35) may improve coronary blood flow and 
thus limit the extent of myocardial necrosis. Two smaller 
studies (36,371 have shown a reduction in early rethrombosis 
after streptokinase administration with tbe use of aspirin 
alone or in combination with dipyridamole. 
With regard to unticoagulat!on, we recommend systemic 
heparinization in all patients undergoing thrombolysis. In 
the study by Guerci et al. (381, a low incidence rate (<a%) of 
recurrent ischemia was found in patients who received r&PA 
for acme myocardial infarction. This low incidence of early 
ischeria was possibly a result of adjunctive therapy with 
high dose heyrrin, aimed at an activated partial thrombo- 
plastin time of two to three times control, which may prevent 
reocclusion by inhibiting thrombin activity. Moreover, in a 
group of patients treated with streptokinase and maintained 
on heparin therapy, recurrent ischemia was observed shortly 
after the discontinuation of heparin (39). The benerits of 
heparin are supported experimentally (40) in a pig model of 
deep arterial injury, in which we found an inverse relation 
between platelet deposition and the dose of heparin used. 
On the basis of these data and while awaiting the com- 
pletion of two large trials (Gruppo Italiano per lo Studio della 
Streptochinasi nell’lnfarto Miocardico [GISSI]-2 and ISIS- 
3). we recommend the use of a high dose intravenous bolus 
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of heparin (100 U/kg) after thrombolysis, followed by a 
maintenance infusion of about 1 ,ttOtl U/h for approximately 5 
days (aimed at an activated partial thromboplastin time of 2 
to 2.5 times control). This regimen may be followed by 
subcutaneous administration of heparin at a dose of about 
10,000 U twice daily. In addition, we recommend concomi- 
tant tiwrapy with aspirin at a dose of 80 mglday. Such a low 
dose is recommended to reduce the risk of gastrointestinal 
bleeding. If revascularization is not done, the patient can be 
discharged on aspirin therapy (I60 to 325 mglday) if he or she 
is at low risk for recurrent thrombotic events. This risk can 
be assessed bv certain clinical and angiographic variables 
that include the patency of the infarct-related artery, the 
presence or absence of a residual thombus or the early 
recurrence of ischemia. High risk patients may benefit from 
a short-term (4 to 6 weeks) combination of low dose aspirin 
and warfarin. Such a combination seemed to be beneficial in 
our short-term pilot study of unstable angina (unpublished 
data) and, if the final results co&m our preliminary impres- 
sion, this recommendation may be extended to postinfarc- 
tion patients treated with thrombolytic agents. 
Future appcnaches. In addition to the thmmbolytic ,nd 
atttithromhotic approaches already mentioned for the pre- 
vention of pustlysis reocclusion, active investigation is cur- 
rently underway in the development of powerful antithrom- 
botic agents or a combination of agents that work through 
different mechanisms. According to preliminary data ob- 
tained in our laboratory, recombinant peptide inhibitors of 
thrombin appear to be very promising in the prevention of 
reocclusion (unpublished data). This approach is aimed at 
the inhibition of thrumbin, which is one of the most impor- 
tant platelet activators. 
Golino et al. (41) demonstrated a reduction in the inci- 
dence of reocclusion with the simultaneous USE of inhibitors 
of thrmboxane A2 and serotonin in an animal model. Al- 
though these results are interesting, these agents only inhibit 
the thromhoxane- and serotortin-dependent pathways of 
platelet activation, leaving intact the most important pathway 
that is dependent on tltrombin and collagen. Therefore, it 
remains to be proved whether these agents are more effective 
in terms of platelet-inhibitory effects than aspitin alone. 
Gold et al. (42) studied the combined effects of H-PA and 
mvnoclonal antiplatelet glycoprotein Mb-llla antibody in an 
animal model. In their elegant study, reperfttsion with r&PA 
was followed rapidly by reocclusion and cyclic periods of 
reflow and reocclusion. When r&PA was given in combina- 
tion with a monoclonal antibody [7E3-F(ab’&l directed 
against the platelet glycoprotein KIb-IlIa receptor, the time 
to reperfttsion was shortened and reocclusion was pre- 
vented. As stated, glycoprotein IIb-IIIa binds fibrinogen and 
von Willehtand factor and is essential in the process of 
pkttelet aggregation. Tterefore, whereas rt-PA or other 
thromLoiytic agents lyse the existing thrombus, a glycopro- 
tein I&Ma blocker produces marked inhibition of platelet 
aggregation by agonists such as !hrombin and collagen (43). 
As a result, platelet/fibrin thrombus formation is inhibited 
and the risk of vessel reocclusion is reduced. The clinical 
applicability of this approach remains to be defined. 
Another approach to the problem of platelet octivorion 
associated with vessel wall injury consists of rhe use of 
blockers of adhesive glycoproteins. In one study (44). hepa- 
rinized carotid blood from pigs was exposed to collagen type 
I at shear rates typical of stenotic arteries and the degree of 
platelets. oretreated with as&c had a 30% reduc- 
tion in platelet deposition as compared with control. When 
animals with severe von Willebrand’s disease were used. we 
found a 90% reduction in platelet deposition. Furthermore, 
when normal pigs were treated with g monoclonal antibody 
directed against porcine von Willebnnd factor, an 81% 
reduction in platelet deposition was seen. In these experi- 
inhibition of von Wil- 
reduction in olatelet 
deposition, not-seen with any of the currently available 
platelet inhibitors. Whether or-not this 
utiiitv remains to -be elucidated. 
approach has clinical 
C&&3hut. The problem of post-thrombolysis reocclu- 
sion is of paramouni clinical importance and is associated 
with signi..~ant morbidity and, perhaps, mortality. This issue 
-.an be approached through several avenues. First, better 
thrombolytic agents with longer duration of etTects and more 
powerful antithrombotic properties aimed at enhanced clot 
lysis are needed. While completion of the GISSI-2 and 
ISIS-3 trials is awaited, the combination of high dose heparin 
and low dose aspirin is proposed for all patients who do not 
have a contraindication to these drugs. Finally, peptide 
inhibitors of thrombin and monoclonal antibodies against 
platelet glycoprotein receptors and adhesive macromol- 
ecules (such as von Wiibrand factor) may prove to be 
powerful, effective inhibitors of platelet aggregation and 
thrombus formation and, therefore, may greatly improve the 
efficacy of thrombolytic therapy. 
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